ONCY — ONCOLYTICS BIOTECH INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1129928 ·
Last close
$0.38
Market Cap
$50.15M
52W High
$1.30
52W Low
$0.33
ADV30
1,298,206
Next earnings
—
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -9,742,000 -9,705,000 5,832,000 2,430,000 13,335,000
Jun 2026 0 — -9,379,000 -9,442,000 7,671,000 4,115,000 13,838,000
Mar 2026 0 — -9,281,000 -9,243,000 8,161,000 5,493,000 13,291,000
Dec 2025 0 — -9,651,891 -9,177,897 7,582,000 5,202,000 11,381,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-26,704,000
Investing CF
$-11,000
Financing CF
$20,228,000
CapEx
$-12,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.32
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-448,180,000
Inventory
—
Receivables
$1,214,000
ST Investments
—
EBIT TTM
$-38,256,205
Pretax Income TTM
$-38,090,657
Interest Exp TTM
—
Analysts
5

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -28,725,000 -28,759,000 7,582,000 11,381,000 -3,799,000 -20,112,000
Dec 2024 0 -25,542,000 -22,794,000 13,421,000 10,123,000 3,298,000 -19,883,000
Dec 2023 0 -25,471,883 -20,919,644 29,262,777 8,485,602 20,777,175 -21,444,294
Dec 2022 0 -19,837,902 -18,298,703 27,508,105 7,981,138 19,526,967 -17,208,223

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$7,671,000
Forward EPS
$-0.20

Peers — same industry

TickerNameMarket CapLastDaily %
PDSB PDS Biotechnology Corp $50.03M $0.89 —
HOWL Werewolf Therapeutics, Inc. $51.03M $1.05 —
APLM Apollomics Inc. $49.09M $16.84 —
MIST Milestone Pharmaceuticals Inc. $51.44M $0.41 —
NMAD NOMAD POWER SOLUTIONS, INC. $48.30M $3.00 —

News headlines (Yahoo Finance, 1h cache)

ONCY: Supply Agreement with Coherus to Evaluate Pelareorep in SCAC with Checkpoint Inhibitor
2026-11-16 13:05 · Yahoo
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC
2026-11-13 17:10 · Yahoo
Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
2026-11-09 14:30 · Yahoo
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
2026-11-04 14:30 · Yahoo
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
2026-10-27 13:30 · Yahoo
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
2026-10-20 13:35 · Yahoo
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
2026-10-14 13:30 · Yahoo
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
2026-10-14 08:07 · Yahoo
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
2026-10-12 20:05 · Yahoo
ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC
2026-08-27 10:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.